Search Results
Your search for Matthew matches 8035 pages
Showing 1 - 50EBRT With Focal Boost in Localized Prostate Cancer: 10-Year Follow-up
As reported in the Journal of Clinical Oncology by Guricová et al, 10-year outcomes of the Dutch-Belgian phase III FLAME trial showed continued benefit of a focal radiotherapy boost to the intraprostatic tumor in patients receiving external-beam radiotherapy (EBRT) for localized prostate cancer....
Breast Cancer Surveillance in Pre– vs Post–COVID-19 Periods
In a study reported as a research letter in JAMA Oncology, Hahn et al found that the proportion of U.S. patients with breast cancer undergoing annual surveillance imaging was lower in the post– vs pre–COVID-19 period, with no significant difference in recurrence or progression being observed. Study ...
Age Threshold for Survival Benefit of Adding Oxaliplatin to Adjuvant Chemotherapy in Stage II and III Colorectal Cancer
In a Korean retrospective study reported in JAMA Network Open, Bong et al found that the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy was associated with an overall survival benefit in patients with stage III colorectal cancer aged ≤ 70 years but not in those aged > 70 ...
Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?
In a substudy of the Australian phase II ENZA-p trial reported in The Lancet Oncology, Emmett et al found that baseline prostate-specific membrane antigen (PSMA)–positron-emission tomography (PET) total tumor volume (TTV) was prognostic for overall survival and predictive for a beneficial effect on ...
Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy
In a French-Belgian phase III trial (ASTER 70s) reported in The Lancet, Brain et al examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic...
Mortality in Advanced-Stage Ovarian Cancer—Effect of Neoadjuvant Chemotherapy and Cytoreductive Surgery Case Volume
In a cross-sectional study reported in JAMA Network Open, Abel et al found that higher rates of neoadjuvant chemotherapy (NACT) and a higher annual volume of cytoreductive surgery were associated with better survival outcomes in patients treated at Commission on Cancer–accredited cancer programs in ...
Combination Therapies for Metastatic or Recurrent Pancreatic Cancer Under Study
In an interim analysis of a Japanese phase II/III trial (GENERATE, JCOG1611) reported in the Journal of Clinical Oncology, Ohba et al compared the survival benefit of mFOLFIRINOX (modified fluorouracil, leucovorin, irinotecan, oxaliplatin) or S-IROX (S-1, irinotecan, oxaliplatin) vs nab-paclitaxel...
Chemotherapy Regimens Compared in High-Grade Serous Ovarian Cancer With No BRCA Mutation
In a phase III trial (EPIK-O/ENGOT-ov61) reported in the Journal of Clinical Oncology, Konstantinopoulos et al compared the survival outcomes of alpelisib plus olaparib vs single-agent chemotherapy in patients with platinum-resistant or -refractory high-grade serous ovarian cancer (HGSOC) with no...
Nivolumab Plus Ipilimumab in Advanced Ovarian and Endometrial Clear Cell Cancers
In an Australian–New Zealand phase II trial (MoST-CIRCUIT) reported in JAMA Oncology, Gao et al found that the combination of nivolumab and ipilimumab showed “encouraging activity” in patients with advanced ovarian and endometrial clear cell cancers. Study Details Twenty-eight patients with...
Nivolumab Plus Ipilimumab in mCRPC With an Immunogenic Signature
In a UK phase II trial (NEPTUNES) reported in the Journal of Clinical Oncology, Leone et al evaluated the efficacy of nivolumab plus ipilimumab in previously treated patients with immunogenic signature–positive metastatic castration-resistant prostate cancer (mCRPC). Study Details The multicenter...
Investigating the Mechanisms of Cardiovascular Adverse Events Linked to Certain Cancer Treatments
The true upside of the many advances in cancer treatment is clear. Approximately 18.6 million people in the United States have a history of cancer, and the number of cancer survivors is expected to exceed 22 million by the year 2035.1However, one downside affecting many of these individuals is the...
Outcomes Associated With COVID-19 Infection in Patients With Cancer
As reported in JAMA Oncology by Rini et al, the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) has identified outcomes associated with COVID-19 in patients with cancer. Study Details Between May 2020 and February 2022, the study enrolled adult patients from sites participating ...
Pediatric CNS Tumors: Long-Term Survival and Cure Fraction Estimates
As reported in The Lancet Oncology by Hoogendijk et al, the EUROCARE-6 population-based study has provided long-term survival rates and cure fraction estimates for pediatric patients with central nervous system (CNS) tumors across 31 European countries. Study Details The study involved data from...
Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
In a phase II study (ENGOT-OV60/GOG-3052/RAMP 201) reported in the Journal of Clinical Oncology, Banerjee et al evaluated the efficacy and safety of the RAF/MEK clamp avutometinib in combination with the FAK inhibitor defactinib in patients with recurrent low-grade serous ovarian cancer. Study...
Pembrolizumab and De-escalation of Treatment in Resectable Cutaneous Squamous Cell Cancer
In an Australian phase II trial (De-Squamate) reported in the Journal of Clinical Oncology, Ladwa et al found that the use of pembrolizumab produced a high rate of clinical or pathologic complete response in patients with resectable cutaneous squamous cell cancer (cSCC), suggesting the potential to ...
Final Overall Survival Analysis in HRR-Deficient Cohort in TALAPRO-2: Addition of Talazoparib to Enzalutamide in Metastatic CRPC
As reported in The Lancet by Fizazi et al, the final overall survival analysis in the homologous recombination repair (HRR)-deficient metastatic castration-resistant prostate cancer (CRPC) cohort of the phase III TALAPRO-2 trial showed a significant benefit with the addition of talazoparib to...
Addition of Talazoparib to Enzalutamide in Metastatic CRPC in Genetically Unselected Cohort
As reported in The Lancet by Agarwal et al, the final overall survival analysis of the phase III TALAPRO-2 trial showed that the addition of talazoparib to enzalutamide resulted in a significant benefit in a cohort of patients with metastatic castration-resistant prostate cancer (CRPC) unselected...
Esophageal Adenocarcinoma Recurrence Patterns With Perioperative Chemotherapy vs Preoperative Chemoradiotherapy
In an analysis from the German phase III ESOPEC trial reported in the Journal of Clinical Oncology, Hoeppner et al found that perioperative chemotherapy reduced distant recurrence vs preoperative chemoradiotherapy in patients with nonmetastatic esophageal adenocarcinoma. The primary analysis of the ...
Extended Outcomes With Addition of Sugemalimab to First-Line Chemotherapy in Metastatic NSCLC
In a 4-year follow-up of the Chinese phase III GEMSTONE-302 trial reported in The Lancet Oncology, Zhou et al examined the survival benefit of adding the PD-L1 inhibitor sugemalimab to first-line platinum-based chemotherapy in patients with metastatic non–small cell lung cancer (NSCLC) with no...
Fertility Outcomes in Patients of Childbearing Potential Receiving First-Line Therapy for Advanced Lymphoma
In an analysis reported in The Lancet Oncology, Ferdinandus et al found that among patients with newly diagnosed advanced-stage classical Hodgkin lymphoma who were of childbearing potential (POCBP) in the phase III HD21 trial, those receiving BrECADD (brentuximab vedotin, etoposide,...
Association of Type 2 Diabetes With Colorectal Cancer Risk and Survival by Tumor Immunity Status
In a German population–based, matched case-control study reported in the Journal of Clinical Oncology, Wankhede et al found that type 2 diabetes (T2D) may be associated with colorectal cancer (CRC) risk and survival according to tumor immunity status. Study Details The study included 1,889 CRC...
HER2DX Assay and Survival Outcomes in HER2-Positive Breast Cancer
In an individual patient-level meta-analysis reported in The Lancet Oncology, Villacampa et al found that the HER2DX assay risk score was prognostic for event-free survival outcomes in patients with early-stage, HER2-positive breast cancer. Study Details Systematic review of the literature...
Breastfeeding Patterns After Treatment of Early Hormone Receptor–Positive Breast Cancer
In a prospective study (POSITIVE) reported in the Journal of Clinical Oncology, Peccatori et al investigated breastfeeding patterns among women who had a live birth after treatment of hormone receptor–positive breast cancer. Study Details Between December 2014 and December 2019, 518 women who...
Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
In a Chinese phase II trial reported in the Journal of Clinical Oncology, Xia et al compared objective response rates seen with camrelizumab plus famitinib vs camrelizumab alone in previously treated patients with recurrent or metastatic cervical cancer. Study Details In the multicenter, open-label ...
DREAMM-7 Analysis Compares Survival Outcomes Between Triplet Regimens for Relapsed or Refractory Multiple Myeloma
In an analysis from the phase III DREAMM-7 trial reported in The Lancet Oncology, Hungria et al compared survival outcomes with belantamab mafodotin, bortezomib, and dexamethasone (BVd) vs daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma...
Extended Follow-up for Neoadjuvant and Adjuvant Relatlimab Plus Nivolumab in Resectable Melanoma
In an extended follow-up of a phase II trial reported in the Journal of Clinical Oncology, Burton et al examined outcomes with neoadjuvant and adjuvant relatlimab-rmbw plus nivolumab in patients with resectable melanoma. Relatlimab targets LAG3, while nivolumab targets PD-1. Study Details In the...
Thyroidectomy Without Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer
In a UK phase III trial (IoN) reported in The Lancet, Mallick et al compared survival outcomes among patients with low-risk differentiated thyroid cancer who underwent thyroidectomy with no postoperative radioiodine ablation vs thyroidectomy plus ablation. Study Details In the multicenter...
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
In an analysis from the French SAMCO-PRODIGE 54 trial reported in JAMA Oncology, Taïeb et al examined survival outcomes associated with a change in ctDNA from baseline to 1 month after start of treatment in patients receiving ICI treatment with avelumab for deficient mismatch repair/microsatellite...
Risk of Liver Cancer With Oral Contraceptive Use
In a UK population-based study reported in The Lancet Oncology, Watling et al examined the relationship between ever use vs never use of oral contraceptives and the risk of liver cancer. Some findings suggested the possibility of slightly increased risk with longer-term use. As noted by the...
Lisocabtagene Maraleucel as Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up
As reported in the Journal of Clinical Oncology by Kamdar et al, the 3-year follow-up of the phase III TRANSFORM trial showed that lisocabtagene maraleucel (liso-cel) maintained superior efficacy vs standard of care (SOC) in second-line treatment of relapsed/refractory large B-cell lymphoma (LBCL). ...
Metformin in Metastatic Prostate Cancer
In a phase III trial (part of the STAMPEDE platform) reported in The Lancet Oncology, Gillessen et al investigated the survival outcomes of adding metformin to standard of care (SOC) in nondiabetic patients with metastatic hormone-sensitive prostate cancer starting androgen-deprivation therapy...
Outcomes With Perioperative Immunotherapy in Resectable NSCLC
In a retrospective cohort study reported in JAMA Network Open, Desai et al examined survival outcomes with the addition of immunotherapy to neoadjuvant or adjuvant chemotherapy in patients with resectable non–small cell lung cancer (NSCLC). Study Details The study involved data from the Flatiron...
Surgery vs Ablation in Small Hepatocellular Carcinoma
In two Japanese studies (SURF-RCT and SURF-Cohort) reported in the Journal of Clinical Oncology, Kawaguchi et al compared the outcomes of surgery vs radiofrequency ablation (RFA) in patients with small hepatocellular carcinoma (HCC). Study Details Two multicenter studies were performed, with...
Ruxolitinib for Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease
In the 3-year final analysis of the phase III REACH3 trial reported in the Journal of Clinical Oncology, Zeiser et al compared the use of ruxolitinib vs best available therapy (BAT) in terms of failure-free survival and duration of response in patients with steroid-refractory or -dependent chronic...
Subsequent Neoplasm Risk Among Childhood Cancer Survivors: Effect of BMI and Physical Activity
In a study reported in JAMA Oncology, Joffe et al examined the association of high body mass index (BMI) and low physical activity with increased risk of subsequent neoplasms among childhood cancer survivors. Study Details The study involved data on 5-year survivors of childhood cancers diagnosed...
Nivolumab or Brentuximab Vedotin With AVD in Older Patients With Advanced Classical Hodgkin Lymphoma
In a subset analysis from the phase III SWOG S1826 trial reported in the Journal of Clinical Oncology, Rutherford et al compared the survival outcomes of nivolumab plus AVD (doxorubicin, vinblastine, dacarbazine; N-AVD) vs brentuximab vedotin plus AVD (BV-AVD) in patients with advanced-stage...
Zanidatamab Plus Chemotherapy in Advanced HER2-Positive Gastroesophageal Adenocarcinoma
In a phase II trial reported in The Lancet Oncology, Elimova et al evaluated the efficacy and safety of the bispecific monoclonal antibody zanidatamab plus chemotherapy in the first-line treatment of patients with advanced HER2-positive gastroesophageal adenocarcinoma. Study Details In the trial,...
Intratumoral BO-112 With Pembrolizumab in Anti–PD-1–Resistant Melanoma
In a Spanish-French phase II trial (SPOTLIGHT-203) reported in the Journal of Clinical Oncology, Márquez-Rodas et al investigated the combination of the intratumoral agent BO-112 and pembrolizumab for activity in patients with advanced anti–PD-1–resistant melanoma. BO-112 is a synthetic,...
Addition of Glofitamab to R-CHOP or Pola-R-CHP in Younger Patients With High-Risk LBCL
In an Australian phase II trial (COALITION) reported in the Journal of Clinical Oncology, Minson et al investigated the addition of glofitamab to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab vedotin, rituximab, cyclophosphamide,...
Bevacizumab Plus Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
In a National Cancer Institute phase II trial reported in The New England Journal of Medicine, Srinivasan et al investigated whether the monoclonal antibody bevacizumab in combination with the EGFR inhibitor erlotinib showed activity in patients with advanced hereditary leiomyomatosis and renal...
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
In a French phase II trial (LEANOX) reported in the Journal of Clinical Oncology, Assenat et al examined survival outcomes and oxaliplatin-induced peripheral neurotoxicity (OIPN) risk associated with lean body mass (LBM)-based oxaliplatin dosing in the adjuvant treatment of stage III colon cancer....
Metastatic Castration-Resistant Prostate Cancer: Comparison of Second-Line Regimens
As reported in The Lancet Oncology by Agarwal et al, the phase III CONTACT-02 trial examined the survival benefit of cabozantinib plus atezolizumab vs switch of androgen receptor pathway inhibitor (ARPI) in patients with castration-resistant prostate cancer with extrapelvic soft-tissue metastases...
HER3-DXd in NSCLC Without EGFR-Activating Mutations
As reported in the Journal of Clinical Oncology by Steuer et al, findings in a cohort of a phase I trial indicated activity of the HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) in patients with advanced squamous or nonsquamous non–small cell lung cancer (NSCLC) without a...
Frontline Triplet Regimens for Intensive Chemotherapy-Ineligible IDH-Mutant AML
In a single-center study reported in the Journal of Clinical Oncology, DiNardo et al investigated whether frontline triplet regimens consisting of a hypomethylating agent, venetoclax, and an isocitrate dehydrogenase inhibitor were active in intensive chemotherapy-ineligible patients with IDH-mutant ...
Partial-Breast Radiotherapy After Breast-Conserving Surgery: 10-Year Outcomes
As reported in The Lancet Oncology by Kirby et al, 10-year follow-up of the phase III UK IMPORT LOW trial has shown that partial-breast and reduced-dose radiotherapy continue to be associated with similar ipsilateral breast tumor recurrence (IBTR) outcomes compared with whole-breast radiotherapy...
Addition of Retifanlimab to First-Line Chemotherapy in Advanced Squamous Cell Carcinoma of the Anal Canal
In a phase III trial (POD1UM-303/InterAACT-2) reported in The Lancet, Rao et al investigated the survival benefit of adding the PD-1 inhibitor retifanlimab to carboplatin-paclitaxel in patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Study Details In the...
Early Toxicity With Moderately Hypofractionated vs Stereotactic Body Radiotherapy in Prostate Cancer
In an analysis from a phase III trial (PACE-C) reported in The Lancet Oncology, Tree et al compared early toxicity rates with intensity-modulated moderately hypofractionated radiotherapy (MHRT) vs stereotactic body radiotherapy (SBRT) in patients with intermediate- and high-risk prostate...
Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer
In an interim analysis of a phase III trial (KEYNOTE-689) reported in The New England Journal of Medicine, Uppaluri et al examined the survival benefit of adding perioperative pembrolizumab to standard care in patients with locally advanced head and neck squamous cell carcinoma. Study Details In...
Addition of Lenvatinib/Pembrolizumab to Chemotherapy in Advanced/Metastatic Gastroesophageal Adenocarcinoma
In an interim analysis of the phase III LEAP-015 trial reported in the Journal of Clinical Oncology, Shitara et al examined the survival benefit of adding lenvatinib-pembrolizumab to chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma. Study Details In the open-label...
Adding Olanzapine to Triplet Antiemetics Post–Anthracycline/Cyclophosphamide Chemotherapy
In a phase III Japanese trial reported in The Lancet Oncology, Saito et al examined the efficacy of adding 5 mg of olanzapine to triplet antiemetic therapy in controlling chemotherapy-induced nausea and vomiting in the overall phase when given after receipt of anthracycline-cyclophosphamide...
